{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:35:46Z","timestamp":1783485346979,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T00:00:00Z","timestamp":1598140800000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejim.2019.07.016","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T08:17:40Z","timestamp":1563869860000},"page":"97-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Cytopenia induced by low-dose methotrexate: An analysis of 433 cases from the French pharmacovigilance database"],"prefix":"10.1016","volume":"67","author":[{"given":"Sophie","family":"Lalev\u00e9e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Laugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-1069","authenticated-orcid":false,"given":"Laurence","family":"Fardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2019.07.016_bb0005","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/1756-185X.12862","article-title":"Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story","volume":"19","author":"Malaviya","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ejim.2019.07.016_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","article-title":"The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions","volume":"44","author":"Kinder","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2019.07.016_bb0015","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2019.07.016_bb0020","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjd.15377","article-title":"Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"177","author":"Mazaud","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2019.07.016_bb0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/art.1780400130","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ure\u00f1a et al","volume":"40","author":"Nygaard","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.07.016_bb0030","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/1756-185X.13004","article-title":"Methotrexate-induced pancytopenia: a case series of 46 patients","volume":"20","author":"Ajmani","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ejim.2019.07.016_bb0035","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/MJT.0000000000000486","article-title":"Fatal cytopenia induced by low-dose methotrexate in elderly with rheumatoid arthritis. identification of risk factors","volume":"24","author":"Mameli","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.ejim.2019.07.016_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2019.07.016_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2019.07.016_bb0050","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Ure\u00f1a","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.07.016_bb0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1744666X.2017.1257939","article-title":"Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations","volume":"13","author":"Maharaj","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ejim.2019.07.016_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British association of dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2019.07.016_bb0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2340\/00015555-2599","article-title":"Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a danish expert meeting","volume":"97","author":"Raaby","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejim.2019.07.016_bb0070","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris\u2014update 2015\u2014short version\u2014EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"10.1016\/j.ejim.2019.07.016_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"10.1016\/j.ejim.2019.07.016_bb0080","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5694\/mja15.01242","article-title":"A decade of Australian methotrexate dosing errors","volume":"204","author":"Cairns","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejim.2019.07.016_bb0085","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/ajhp\/61.13.1380","article-title":"Reported medication errors associated with methotrexate","volume":"61","author":"Moore","year":"2004","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"key":"10.1016\/j.ejim.2019.07.016_bb0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/15563650.2016.1271126","article-title":"What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?","volume":"55","author":"Chan","year":"2017","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"10.1016\/j.ejim.2019.07.016_bb0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","article-title":"Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration","volume":"33","author":"Bianchi","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2019.07.016_bb0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1586\/ecp.11.57","article-title":"Pharmacokinetic drug-drug interactions with methotrexate in oncology","volume":"4","author":"Lev\u00eaque","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejim.2019.07.016_bb0105","series-title":"Th\u00e9saurus des interactions m\u00e9dicamenteuses","author":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament","year":"2018"},{"key":"10.1016\/j.ejim.2019.07.016_bb0110","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3899\/jrheum.090153","article-title":"Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review","volume":"37","author":"Bourr\u00e9-Tessier","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2019.07.016_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1060028016672035","article-title":"Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors","volume":"51","author":"Hall","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejim.2019.07.016_bb0120","first-page":"309","article-title":"Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice","volume":"94","author":"Grove","year":"2001","journal-title":"QJM Mon J Assoc Phys"},{"key":"10.1016\/j.ejim.2019.07.016_bb0125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/tpj.2017.34","article-title":"Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis","volume":"18","author":"Zhu","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ejim.2019.07.016_bb0130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/1756-185X.13100","article-title":"Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis","volume":"20","author":"Fan","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ejim.2019.07.016_bb0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/pgs-2016-0158","article-title":"Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? a systematic review and meta-analysis","volume":"18","author":"Chen","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejim.2019.07.016_bb0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11531070-000000000-00000","article-title":"Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis","volume":"30","author":"Lee","year":"2010","journal-title":"Clin Drug Investig"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519302353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519302353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:29:43Z","timestamp":1760606983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620519302353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":28,"alternative-id":["S0953620519302353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.07.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytopenia induced by low-dose methotrexate: An analysis of 433 cases from the French pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}